Literature DB >> 22327855

Current status of postoperative follow-up for lung cancer in Japan: questionnaire survey by the Setouchi Lung Cancer Study Group-A0901.

Shigeki Sawada1, Hiroshi Suehisa, Motohiro Yamashita, Masao Nakata, Norihito Okumura, Kazunori Okabe, Hiroshige Nakamura, Hirohito Tada, Shinichi Toyooka, Hiroshi Date.   

Abstract

PURPOSE: There is no recommended standard follow-up program after resection for lung cancer. Under these circumstances, each doctor establishes his or her own follow-up protocol. This questionnaire survey was conducted to grasp the current status of postoperative follow-up in Japan.
METHODS: The questionnaire survey was aimed at determining what examinations were performed and at what frequencies in the setting of postoperative follow-up. Based on these results, examinations performed at a frequency of >50% and the time points after resection at which they were performed were selected and presented as components of an average follow-up program.
RESULTS: Questionnaires were sent to 44 institutions, and 26 doctors responded to the questionnaire. All 26 of the doctors performed physical examinations, blood examinations, chest radiography, and computed tomography (CT) routinely, but their frequencies varied widely among the doctors. The average frequencies of the follow-up examinations as judged from this survey are as follows: Physical and blood examinations are performed three to four times a year for the first 3 years and twice a year during the next 2 years. CT is scheduled at 6 and 12 months after resection and is repeated annually thereafter. Chest radiography is performed three to four times a year for the first 3 years and once a year thereafter, between the CT examinations.
CONCLUSION: The follow-up programs used in clinical practice vary widely among institutions and doctors in terms of the types of examination performed and the frequencies at which they are performed.

Entities:  

Mesh:

Year:  2012        PMID: 22327855     DOI: 10.1007/s11748-011-0850-9

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  15 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

3.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC).

Authors:  E Felip; R A Stahel; N Pavlidis
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

4.  The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.

Authors:  R J Hicks; V Kalff; M P MacManus; R E Ware; A F McKenzie; J P Matthews; D L Ball
Journal:  J Nucl Med       Date:  2001-11       Impact factor: 10.057

5.  Is follow-up of lung cancer patients after resection medically indicated and cost-effective?

Authors:  G L Walsh; M O'Connor; K M Willis; M Milas; R S Wong; J C Nesbitt; J B Putnam; J J Lee; J A Roth
Journal:  Ann Thorac Surg       Date:  1995-12       Impact factor: 4.330

6.  Cost of patient follow-up after potentially curative lung cancer treatment.

Authors:  K S Virgo; K S Naunheim; L W McKirgan; M E Kissling; J C Lin; F E Johnson
Journal:  J Thorac Cardiovasc Surg       Date:  1996-08       Impact factor: 5.209

7.  Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition).

Authors:  Jeffrey Rubins; Michael Unger; Gene L Colice
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

8.  PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.

Authors:  Zohar Keidar; Nissim Haim; Luda Guralnik; Mirjana Wollner; Rachel Bar-Shalom; Alon Ben-Nun; Ora Israel
Journal:  J Nucl Med       Date:  2004-10       Impact factor: 10.057

9.  Post-treatment management options for patients with lung cancer.

Authors:  K S Virgo; L W McKirgan; M C Caputo; D M Mahurin; L C Chao; N A Caputo; K S Naunheim; M W Flye; K N Gillespie; F E Johnson
Journal:  Ann Surg       Date:  1995-12       Impact factor: 12.969

10.  Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients.

Authors:  Daisuke Takenaka; Yoshiharu Ohno; Hisanobu Koyama; Munenobu Nogami; Yumiko Onishi; Keiko Matsumoto; Sumiaki Matsumoto; Takeshi Yoshikawa; Kazuro Sugimura
Journal:  Eur J Radiol       Date:  2009-04-23       Impact factor: 3.528

View more
  3 in total

Review 1.  A proposal of postoperative follow-up pathways for lung cancer.

Authors:  Shigeki Sawada; Satoshi Shiono; Yoshinori Yamashita; Tsutomu Tagawa; Hiroyuki Ito; Toshihiko Sato; Hiroaki Harada; Motohiro Yamashita
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-12-18

2.  Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.

Authors:  Christopher T Erb; Kevin W Su; Pamela R Soulos; Lynn T Tanoue; Cary P Gross
Journal:  Lung Cancer       Date:  2016-07-19       Impact factor: 5.705

3.  Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection.

Authors:  Ching-Yang Wu; Jui-Ying Fu; Ching-Feng Wu; Ming-Ju Hsieh; Yun-Hen Liu; Yi-Cheng Wu; Cheng-Ta Yang; Ying-Huang Tsai
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.